Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Liminal BioSciences announces FDA approval for its BLA of Ryplazim to treat patients with plasminogen deficiency type 1

Written by | 13 Jun 2021

Liminal BioSciences Inc. announced that the FDA has approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.